The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Stephen L Abrams1, Linda S Steelman, John G Shelton

  • 1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.

Insights

Targeting the Raf/MEK/ERK and PI3K/Akt/mTOR pathways may treat drug-resistant cancers. The Raf/MEK/ERK pathway significantly impacts drug sensitivity, while Akt-1 is crucial for long-term growth and resistance.

Area of Science:

  • Cellular signaling pathways
  • Cancer biology
  • Drug resistance mechanisms

Background:

  • The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways regulate critical cellular processes.
  • Understanding these pathways is vital for cancer therapy.

Purpose of the Study:

  • To investigate the role of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in drug resistance.
  • To examine their effects on cell proliferation, apoptosis, and sensitivity to inhibitors.

Main Methods:

  • Utilized FL/DeltaAkt-1:ER*(Myr(+)) + DeltaRaf-1:AR cells, conditionally transformed for growth upon Raf and Akt activation.
  • Isolated drug-resistant cells by exposing cells to doxorubicin.
  • Assessed IC50 values for doxorubicin and evaluated effects of pathway activation and inhibition.

Main Results:

  • Raf-1 activation increased doxorubicin IC50 80-fold in resistant cells; Akt-1 activation alone had no effect on IC50.
  • Akt-1 activation enhanced proliferation and clonogenicity in the presence of chemotherapeutic drugs.
  • Doxorubicin-induced apoptosis in resistant cells was enhanced by mTOR and MEK inhibitors.

Conclusions:

  • The Raf/MEK/ERK pathway profoundly influences sensitivity to chemotherapeutic drugs.
  • Akt-1 activation is essential for long-term growth and drug resistance.
  • Targeting these signaling pathways offers a potential therapeutic strategy for drug-resistant cancers with activating mutations.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...